AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 201 min read$NKTR

ROBIN HOWARD W sold $30K of NKTR

ROBIN HOWARD W (President & CEO) sold 418 shares of NEKTAR THERAPEUTICS (NKTR) at $71.98 on 2026-08-18.

Original reporting
SEC EDGAR · ROBIN HOWARD W
Published Aug 20, 2026, 11:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 20, 2026, 11:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$NKTR
Neutral
high confidence
Mentioned
$NKTR
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NKTRNeutralLow
01

Why it matters

The sale is a routine insider transaction with limited market effect.

02

Market read

Minor relevance; investors may note the sale but unlikely to adjust positions.

03

What to watch

Potential upcoming clinical data or financing needs not disclosed.

Relevance 3/10Novelty 4/10Timing: post-market filing on 2026-08-20

Background

Form 4 filing discloses insider transactions required by SEC.

Company-level read

Ticker impact

$NKTRNeutralHigh confidence
Context

CEO Robin Howard sold 418 shares of NKTR for $30,087.64 on 2026-08-18.

Expected impact

minimal impact; price likely unchanged

Evidence & confidence

The transaction size is modest relative to holdings and market cap; no broader implications.

Market effects

Sector

No immediate sector impact; biotech sector unchanged.

Regional

U.S. market only; no regional ripple.

Global

Limited global relevance.

Counterpoint

What could challenge this read

If insiders are selling, it could signal concerns not reflected in price.

Key entities

  • Person
    Robin Howard W

    President & CEO of Nektar Therapeutics

  • Company
    Nektar Therapeutics

    Biopharmaceutical company (NASDAQ: NKTR)

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

NKTR insider trading history →

Related articles

OCT 8
$LLYLow

Nektar v. Lilly: Lilly Defeats CRE Claim, But Jury Finds It Owes $90M For Breaching The Implied Covenant Of Good Faith And Fair Dealing

A federal jury ruled that Eli Lilly & Co. breached the implied covenant of good faith and fair dealing with Nektar Therapeutics, awarding Nektar $90 million in damages. The jury rejected Nektar's claim that Lilly breached the license agreement's commercially reasonable efforts (CRE) obligation. Lilly plans to appeal, arguing no liability should have been imposed. The case highlights risks in biopharma licensing agreements.

mondaq.com2 min
OCT 7
$NKTRLow

Nektar Therapeutics (NKTR): $115 Million Lawsuit Victory Over Eli Lilly Clears Multi-Year Overhang

Nektar Therapeutics (NKTR) won a $115 million lawsuit against Eli Lilly (LLY), resolving a multi-year overhang. The verdict, including interest, amounts to ~5% of NKTR's market cap. Despite the win, NKTR's stock fell over $200 million in market cap due to market volatility and rising yields. Cedar Grove Capital Management views this as a net positive for NKTR, removing a long-standing uncertainty.

finance.yahoo.com2 min
OCT 1
$NKTRMedAI 8/10

NKTR Stock Eyes Worst Day In Over 3 Years On Rezpeg Data: William Blair Still Sees A Durability Edge

Nektar Therapeutics (NKTR) shares fell 21% after reporting modest new response rates for its experimental skin drug, rezpegaldesleukin, in alopecia and eczema studies. Despite this, analysts at William Blair and Jefferies maintained bullish ratings, citing the drug's durability advantage. The company also faces an ongoing legal dispute with Eli Lilly.

newsable.asianetnews.com2 min